Case Report: Increased FGF23 and new insufficiency fractures at burosumab discontinuation in X-linked hypophosphatemia
Burosumab, a monoclonal antibody that binds and inhibits FGF23 activity, was approved in 2018 for treatment of children and adults with X-linked hypophosphatemia (XLH), an X-linked dominant disorder due to increased serum fibroblast growth factor 23 (FGF23) concentration. XLH presents with chronic h...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2025-10-01
|
| Saila: | Frontiers in Endocrinology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1665649/full |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|